<SEC-DOCUMENT>0001193125-14-006615.txt : 20140109
<SEC-HEADER>0001193125-14-006615.hdr.sgml : 20140109
<ACCEPTANCE-DATETIME>20140109160615
ACCESSION NUMBER:		0001193125-14-006615
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140109
DATE AS OF CHANGE:		20140109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AtriCure, Inc.
		CENTRAL INDEX KEY:			0001323885
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				341940305
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51470
		FILM NUMBER:		14518877

	BUSINESS ADDRESS:	
		STREET 1:		6217 CENTRE PARK DRIVE
		CITY:			WEST CHESTER
		STATE:			OH
		ZIP:			45069
		BUSINESS PHONE:		513-755-4107

	MAIL ADDRESS:	
		STREET 1:		6217 CENTRE PARK DRIVE
		CITY:			WEST CHESTER
		STATE:			OH
		ZIP:			45069
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d655991d8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML><HEAD>
<TITLE>Current Report</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;9, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ATRICURE, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-51470</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>34-1940305</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6217 Centre Park Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>West Chester, OH</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>45069</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (513)&nbsp;755-4100 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02. Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;9, 2014, AtriCure, Inc. (&#147;AtriCure&#148; or the &#147;Company&#148;) issued a press release regarding its financial results for the fourth
quarter and full year ended December&nbsp;31, 2013. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item&nbsp;2.02 to Form 8-K and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section. The information in Item&nbsp;2.02 of this Form 8-K and
Exhibit 99.1 shall not be incorporated by reference in any filing or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:11.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated January 9, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">ATRICURE, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: January&nbsp;9, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ M. Andrew Wade</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">M. Andrew Wade</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Vice President and Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d655991dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g655991g34b64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AtriCure, Inc.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andy Wade </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President and Chief Financial Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(513) 755-4564 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">awade@atricure.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lynn Pieper </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(415) 202-5678 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lynn.pieper@westwicke.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AtriCure Announces
Preliminary Results for Fourth Quarter and </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Full Year 2013 and Issues 2014 Guidance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WEST CHESTER, Ohio &#150; January&nbsp;9, 2014 &#150; AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced
preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary revenue for the fourth quarter of
2013 is expected to be approximately $21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on this preliminary estimate, revenue from U.S. customers is expected to be $16.4 million, reflecting growth of 20%,
and revenue from international customers is expected to be $5.5 million, reflecting growth of 17%, or 14% on a constant currency basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary
revenue for full year 2013 is expected to be $81.9 million, reflecting year over year growth of 17% over full year 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to report
preliminary fourth quarter and full year 2013 results which reflect accelerating growth throughout the year and provide a strong platform from which we can continue to build. As we look forward to 2014, we have reason to be excited about our
prospects &#150; we are firmly establishing AtriCure as the leader in training and education on atrial fibrillation. Further, we recently strengthened our position through the acquisition of Estech. We are providing our outlook for 2014 which
anticipates continued revenue growth. I look forward to providing additional detail on our growth strategy when we release our final 2013 results in late February,&#148; said Mike Carrel, President and Chief Executive Officer of AtriCure. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2014 Financial Guidance </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management projects that 2014 revenue will be in the range of $100 million to $103 million, which represents an increase of 22% to 26% over 2013. Organic
revenue growth is expected to be approximately 13%&#150;15% with the remaining portion expected from the recently acquired Estech ablation and valve products. We estimate Estech&#146;s valve products, which are distinct from the core ablation
franchise, to generate revenue of approximately $3 million for the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of
$9 to $10 million for 2014, of which approximately $3.5 million will be transaction related expenses. AtriCure expects the Estech transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About AtriCure, Inc. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AtriCure, Inc. is a medical
device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure&#146;s Synergy Ablation System is the first and only device
approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure&#146;s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.&nbsp;The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than
5.5&nbsp;million people worldwide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Forward-Looking Statements </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates (including projections and guidance), other predictions of
financial performance, launches by AtriCure of new products and market acceptance of AtriCure&#146;s products. Forward-looking statements are based on AtriCure&#146;s experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure&#146;s control. These risks and uncertainties include the rate and degree of
market acceptance of AtriCure&#146;s products, AtriCure&#146;s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability
to obtain reimbursement of procedures utilizing AtriCure&#146;s products, AtriCure&#146;s ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into AtriCure&#146;s operations, AtriCure&#146;s ability
to recognize the benefits of acquisitions, including potential synergies and cost savings, failure of an acquisition or acquired company to achieve its plans and objectives generally, risk that proposed or consummated acquisitions may disrupt
operations or pose difficulties in employee retention or otherwise affect financial or operating results, competition from existing and new products and procedures or AtriCure&#146;s ability to effectively react to other risks and uncertainties
described from time to time in AtriCure&#146;s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility.
AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g655991g34b64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g655991g34b64.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``L`-<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBJ&MZD
MFDZ/=7SG_4QDJ/5N@'YTTKNR$VDKL\X\;>*=0/B.:WT^_GMX;8",B*0J&;N3
MCWX_"NS\#:R^L^'8VGD,ES;L8I68Y+$="?J,5YK8:#<:MH6J:R2Q:W8,/]LY
MR_Y`YK3^&VK?8=?-D[8BO5VC_?'(_J*]"I3BZ34=T>92JR55.6TCUJBBN.\<
M^+QH\!TZQ<?;I5^9A_RQ4]_J>U<,(.;LCT9S4(\S.HM;^VO);B.WD$AMY/+D
M(Z!L9Q^M6:\N\$>+=+T'3+B#4'F\V6<R#:A;(P._X5W>E^)M+U>RFO;>8QP0
MMM=YAL`.,]ZNI2E![:&=*M&:6NIK45S8\=:1/J]OIEDSW4D\@3S$&$7\3U_"
MJ^M_$+2](NVM8HY+R5#A_+("J?3)ZFI5*;=K%.M32O<N>-Y;^'PM<OIQ<2C&
M]H_O!,_,17$_#>ZU*3Q$8TEFDM3&QG#,2H/8\]\UW]EXETZZT.'5IIEM()0<
M"=@#P2#]>E4]'\7:3JFLG3=,A8C8TC3!`BG&.@ZGK6L92C3E'E,9QC*I&?,=
M$2`"2<`=2:Y/5_%CF1H--P`#@S$9)_W15OQ=J+6]HEG$V&GY<CLO_P!>J7A'
M2DF9K^9=PC.V('U[FO&KU9SJ>QINW=GL4:<8T_:SU[(K1Z)KVI*)9I'4-T\Z
M4@_E4=QHNM:8IF1G*KR6AD/'X5WE%-X"%MW?N)8R=]E8PO"M_=7]G+]IE,AC
M<*K$<XQWK=JC:V*:=)=R0H=DS!PBCD''.*IGQ7I@?83,&!P08^AK:$E2@HU)
M:F4HNI-N"T-JBD!R`:R[SQ%8V%PUO<"9'7_8X(]16TIQ@KR=C*,92=HHU:*@
MMKR&ZM$NHVQ$XW`MQQ6==>)]/MY1%$YN)"P&(^@_&E*K"*NV.-.4G9(V**R-
M4\1V>F2>20TTPZHG\/U-6=*U./5K0W$<;1@,5*MZTE6@Y\B>HW3FH\S6A>HK
M+U/Q!8Z8_E2,TDHZHG)'U]*H6_C.RDD"S02Q*3][A@*F6(I1ERN6I4:%22ND
M='15"XU:&%DVJ9$==V]3Q@],453K4T[-DJE-]"_7GWQ1U7;#:Z1$>7/FR`>@
MX4?GG\J]`)"@LQP`,DUXEJVL2:GXLEU1(#<JDP,<>"044\9QVX_6N[#0O._8
MX,5/EAR]SU3PUHR:9X9M["5`2\>9@>Y;J/UQ7D.I6L_A_P`0RP(2LEI-NC;U
M`.5/Y8KK/^%DZ[_T!8_^^)*YGQ'JUUKM\M_=6`M7"!&*JP#8Z9SWKIHPG&3Y
MNIS5YTY02CNCV?2[^/4],M[Z+[L\8;Z'N/SKAOB/HNG66FI?6]JJ7,UQ^\ER
M26R">YJQ\+]6\ZPN-*D;YH&\R,?[)Z_D?YU/\4?^1?M_^OD?^@FN>$7"ORG1
M.2J8?F,OX?>'])U?2+B;4+*.XD2?:K,3P-HXX-=S::#I5C:2VEM8Q)!,<O'C
M(8XQWKF/A9_R`KO_`*^3_P"@BNWJ:\I>T:N7AX1]FG8\"9Y-/UB0V9*R13,L
M1'4<D"O0M,^&5@=-5M3FG:[D7+&-\!">WO7&:?&LOC>%'&5-_P`C_@=>W5T8
MBI*-E$YL+2C.[D<C=^&H;/P#<:?=+',]I%*\4NWD?,64^W:N1^&?_(U'_KW?
M^8KTOQ#_`,B[J/\`U[2?^@FO-/AG_P`C5_V[/_,5%.3=*;9=6*C6@D=#XMD+
MZVRGHD:@?SKIO#2A-!ML=P2?S-<]XP@,>JI-CY98QS[C_(K7\(7:S:6;<GYX
M&/'L>1_6OG*#MBYI]3Z"JKX:+1R?Q"\2ZE!J_P#9=G<26T,2*SF,[6<GGKZ5
M-\.O$FH7FH2:7>SO<1F,R1O(<LA&.,^G-=!XG\%VGB21+CSFMKE%V^8JY##T
M(J3POX/M/#0DE25KBYE&UI6&,#T`[5]#[2E['EMJ>"J=7VW-?0Z&O/-<4+X@
MN0!@>:#_`"KT.O/=>_Y&&X_ZZ#^0KP\Q_AQ]3V\#\;]#T!?N#Z5Q_C0`:A;G
M')B_K78+]P?2N/\`&G_'_;_]<C_.KQW\!_(C"?QD;^@*&T"T5@""G((]S7%Z
MM&MIK5PL("JDF5`Z#O7:^'O^0#:?[G]37':X-WB&X!Z&4#^5<V+7[B'R_(WP
MS_?3^?YFUIGA>*\M1=ZB\C2S_/A6QC/K[U;,?_",Z)=;'WYDS"3UR0`,_2MQ
M`%15'0#%<_XS)_LN$#H9AG\C73.E"C2<XK5+<PC4E5J*,GHV9_A?2TU">6]N
MQYH1L`-SN;J2?6M?Q%I5O/I<DL<*)+"-RLJXX'45S^AZ3=:E;R-;Z@UN$?!0
M$_GP:TF\*Z@RE6U=R#P0=V#^M<U%-T.54[WZZ&]5I5;N=K=-1?!T_G0S6\@#
M>20T>1D@'.1^GZT5<T/0)-(N))6N%E#IMP%QWHKNPL)1I)36IR8B495&X[%?
MQUK`TGPY,JOB>Z_<QCOSU/X"L?X6Z:(M.N=28?-._EH?15Z_J?TK:U;P;I^O
M7(N=0N;R1E&%42@*@]`,5>T30[;0+=K2SEG:$DL$E8-M/?'%>E=1H\JW9YMG
M*MS/9&I63XGTL:QX>N[3&7*;H_9AR*UJBN(S+`\8D>/>-NY,9&?3-<\6TTT=
M,DG%IGB/A?5O[$\06UVQ(BW;)?\`=/!_+K^%=_\`$U3+X9@FC^9!<*<CD8(.
M#4G_``K+0#U>\_[_``_PK:@\/V<>C/H\KS7-H5VA9WW%1Z`X'3M7;5J1<U-=
M#@I4Y*$J;ZG%?#GQ#INFV=W9WURELS2>8C2'`88P1GUXKN-)UVUUN:X^P$R6
M\!"F?&`[=2!]!CGWKS>3PE8+XA_L\37/D[\9W+NQ]=M>EVND6NG:2--L=]O$
M!MW(?GR>IR>_O4XB,;\RW9>&E.W*]D>1:6RCQS`V1C[?U_X'7MM<@GPUT*.1
M9$EO0ZG<&$PR#Z]*ZR(%8E4NSD#&YNIJ<1)2LT7AHN%TRAXC8+X;U$DX'V:3
M_P!!->:_#0@>*P">3;N!^E>FZOI<6L6+6-Q+-'#)]\1,%+#TSCI6-8>`=)TJ
M]CO;.>\CFB.5/F@_@>.E%*25.2?456+=6,ET-;7-*&JV)C7`F3YHR?7T_&N)
ML[N[T74-X4I(AVO&W<>AKT?M5._TFRU)1]IA#,.CCAA^->/B<-SOVD':2/7H
M5^1<DE=,IVGBG3+B,&27[._=9!_6DN_%6F6Z'RI#</V5!Q^=8.HZ%;6LI6.2
M8CW(_P`*OZ3X;L)U\V;S9,?PEL`_D*YXXFO)\BM?N;2H48KGUL6?#M_>:I=W
M5W<*1%@+&!]T=>!ZUS_B6-H=>G)'WMKK[\5WL<4<,:QQ(J(HP%48`K.UO2;7
M4;?S)@PDB'RNAP?I6U?#R="S=VM3.C6BJUTM'H,MO$>FO9)+)=)&P4;D/W@?
MI7):YJ1U2^^T!"L0&V/(Z@5I:5H%G=7!$S2LJ]MP&?TK6O=$LKN_MH&5DBBB
M.U(S@=:YYNKB*6K21M%4J-32Y+X9N8IM%@C5U+Q@JRYY'-<GK1'_``D-P<\"
M8?TKNK:PM;&(I:PI%QU4<_G69)X3TZ61I)'N&=SEB9.I_*ML12FZ4(:71E1J
M1524NC-L'*@^U9VO6#:CI4L*#,B_.@]2.U7;>+R(5B#LX08!<Y.*EKO<5.%G
MU.1-PE==#SW1-6;1[UBZL8G^61>X]_J*[!?$&DM'O^VQ@>AX/Y56UK0;&Z5[
MHJT<O=HSC=]16'INA6MU<[)7FV@]F`_I7E1G6PTO9*S1Z$HTJZ]H[HZ33M57
M5;J4VP86T(P788WL?3Z8_6BKMK:PV<"P6\82->@%%>K!24?>>IYTW%OW=C__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
